Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Aradhye

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 24, 2009
Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year resultsG Comi, P O'Connor, X Montalban, et al.
Transplantation Proceedings|January 1, 1998
Decreased rejection episodes in African-American renal transplant recipients receiving mycophenolate mofetil/tacrolimus therapyM Weber, S Deng, J Arenas, et al.
Transplantation Proceedings|February 1, 1997
Single center analysis of mycophenolate mofetil and Neoral/prednisone therapy for prophylaxis of rejection in African-American and Caucasian transplant recipientsM Weber, R J Ketchum, M Sellers, et al.
Journal of Clinical Pharmacology|June 27, 2000
Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparableL M Shaw, M Korecka, S Aradhye, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|October 26, 2006
FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and AustralasiaM Salvadori, K Budde, B Charpentier, et al.
Transplantation|March 9, 2000
Identification of alpha3, alpha4, and alpha5 chains of type IV collagen as alloantigens for Alport posttransplant anti-glomerular basement membrane antibodiesR Kalluri, A Torre, C F Shield, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 25, 2009
Proof of concept studies for tissue-protective agents in multiple sclerosisL R Mehta, S R Schwid, D L Arnold, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 24, 2009
Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year resultsG Comi, P O'Connor, X Montalban, et al.
Transplantation Proceedings|January 1, 1998
Decreased rejection episodes in African-American renal transplant recipients receiving mycophenolate mofetil/tacrolimus therapyM Weber, S Deng, J Arenas, et al.
Transplantation Proceedings|February 1, 1997
Single center analysis of mycophenolate mofetil and Neoral/prednisone therapy for prophylaxis of rejection in African-American and Caucasian transplant recipientsM Weber, R J Ketchum, M Sellers, et al.
Journal of Clinical Pharmacology|June 27, 2000
Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparableL M Shaw, M Korecka, S Aradhye, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|October 26, 2006
FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and AustralasiaM Salvadori, K Budde, B Charpentier, et al.
Transplantation|March 9, 2000
Identification of alpha3, alpha4, and alpha5 chains of type IV collagen as alloantigens for Alport posttransplant anti-glomerular basement membrane antibodiesR Kalluri, A Torre, C F Shield, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 25, 2009
Proof of concept studies for tissue-protective agents in multiple sclerosisL R Mehta, S R Schwid, D L Arnold, et al.
Pageof 2